# A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

Source: https://onco.cc/trials/nct06593522/  
OnCo record `nct06593522` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Anvumetostat in non-small-cell lung cancer, run by Amgen, active and no longer recruiting.

## Summary

A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) is a phase 2 interventional study registered as NCT06593522 by Amgen, with 61 participants enrolled, started 2024-12-26 and due to reach its primary completion in 2026-10-31. Interventions recorded: anvumetostat.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06593522
- Phase: 2
- Setting: A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
- Sponsor: Amgen
- Enrolled: 61

## Sources

- ClinicalTrials.gov NCT06593522: https://clinicaltrials.gov/study/NCT06593522

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Anvumetostat](https://onco.cc/drugs/anvumetostat/)
- companies: [Amgen](https://onco.cc/companies/amgen/)

---
JSON: https://onco.cc/api/v1/entities/nct06593522.json